Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Center for Neurologic Study-Lability Scale (CNS-LS)score of 13 or greater~* Clinical diagnosis of Pseudobulbar Affect (PBA)~* Documentation of Neurologic disease or brain injury~Exclusion Criteria:~* Unstable neurologic disease~* Severe dementia~* Stroke within 3 months~* Penetrating TBI~* Contraindications to Nuedexta~* Severe Depressive Disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nuedexta (DM 20 mg/Q 10 mg) (Type: OTHER): Single Arm, Open Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).